v3.26.1
SEGMENT INFORMATION (Tables)
12 Months Ended
Dec. 31, 2025
SEGMENT INFORMATION  
Schedule of disaggregated amounts of research and development expenses

  ​ ​ ​

For the years ended December 31,

  ​ ​ ​

2023

  ​ ​ ​

2024

  ​ ​ ​

2025

US$

US$

US$

Direct research and development expenses(a)

 

13,114,341

 

10,399,305

 

6,962,065

Indirect research and development expenses(b)

Payroll and other related costs of personnel

 

18,491,694

 

14,488,811

 

11,493,983

Lab supplies and other research and development expenses

 

5,033,111

 

3,893,296

 

3,577,525

Total indirect research and development expenses

 

23,524,805

 

18,382,107

 

15,071,508

Total research and development expenses

 

36,639,146

 

28,781,412

 

22,033,573

Note (a): Direct research and development expenses consist principally of: (1) costs related to clinical trials such as payments to CRO, CDMO, investigators, and clinical trial sites that conduct the clinical studies; and (2) costs to develop the product candidates, including costs related to product testing.

Note (b): Indirect research and development expenses are not allocated directly to each program, and primarily consist of compensation and other personnel related costs, overhead and infrastructure costs to maintain our facilities, and other costs related to activities that benefit multiple projects.